TherapeuticsMD, Inc.TXMDNASDAQ
LOADING
|||
EPS Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
-78.99%
↓ 5184% below average
Average (39q)
1.55%
Historical baseline
Range
High:253.47%
Low:-357.99%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -78.99% |
| Q2 2025 | 184.25% |
| Q1 2025 | -357.99% |
| Q4 2024 | 141.48% |
| Q3 2024 | 44.13% |
| Q2 2024 | -48.58% |
| Q1 2024 | 16.97% |
| Q4 2023 | 76.06% |
| Q3 2023 | -33.33% |
| Q2 2023 | 35.14% |
| Q1 2023 | 89.58% |
| Q4 2022 | -13.42% |
| Q3 2022 | -124.40% |
| Q2 2022 | 253.47% |
| Q1 2022 | -66.20% |
| Q4 2021 | 10.50% |
| Q3 2021 | -3.88% |
| Q2 2021 | 4.59% |
| Q1 2021 | 24.90% |
| Q4 2020 | -25.83% |
| Q3 2020 | 37.24% |
| Q2 2020 | 8.95% |
| Q1 2020 | -11.23% |
| Q4 2019 | -42.60% |
| Q3 2019 | 42.18% |
| Q2 2019 | -39.63% |
| Q1 2019 | 0.73% |
| Q4 2018 | -5.90% |
| Q3 2018 | -1.69% |
| Q2 2018 | -36.23% |
| Q1 2018 | -13.74% |
| Q4 2017 | -40.23% |
| Q3 2017 | 27.07% |
| Q2 2017 | 9.53% |
| Q1 2017 | 7.92% |
| Q4 2016 | 8.79% |
| Q3 2016 | -18.62% |
| Q2 2016 | 0.00% |
| Q1 2016 | -9.37% |
| Q4 2015 | 10.56% |